We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

20 hedge funds and large institutions have $4.76M invested in Evoke Pharma in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.03% less ownership

Funds ownership: 0.13% → 0.1% (-0.03%)

26% less funds holding

Funds holding: 27 → 20 (-7)

26% less capital invested

Capital invested by funds: $6.45M → $4.76M (-$1.69M)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 7

Holders
20
Holders Change
-7
Holders Change %
-25.93%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
5
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$34.2K
2
Northern Trust
Northern Trust
Illinois
+$9.21K
3
BlackRock
BlackRock
New York
+$1.32K

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$857K
2
BRF
B. Riley Financial
California
-$249K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$58K
4
VF
Virtu Financial
New York
-$48K
5
Macquarie Group
Macquarie Group
Australia
-$32K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.05M -$3.95K -12 -0.3%
SOMRS
2
State of Michigan Retirement System
Michigan
$832K – – –
SFM
3
Sphera Funds Management
Israel
$819K -$857K -2,606 -49%
KCM
4
Knoll Capital Management
Florida
$572K – – –
Deutsche Bank
5
Deutsche Bank
Germany
$416K – – –
6CM
6
683 Capital Management
New York
$238K – – –
Creative Planning
7
Creative Planning
Kansas
$208K – – –
BlackRock
8
BlackRock
New York
$138K +$1.32K +4 +0.9%
California Public Employees Retirement System
9
California Public Employees Retirement System
California
$76K – – –
Northern Trust
10
Northern Trust
Illinois
$71K +$9.21K +28 +13%
Commonwealth Equity Services
11
Commonwealth Equity Services
Massachusetts
$67K – – –
PNC Financial Services Group
12
PNC Financial Services Group
Pennsylvania
$57K +$34.2K +104 +120%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$52K – – –
JGC
14
J. Goldman & Co
New York
$52K – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
$47K – – –
UCFA
16
United Capital Financial Advisors
Texas
$32K – – –
Wells Fargo
17
Wells Fargo
California
$11K -$27.6K -84 -71%
Morgan Stanley
18
Morgan Stanley
New York
$9K -$1.97K -6 -16%
UBS Group
19
UBS Group
Switzerland
$6K -$987 -3 -13%
Citigroup
20
Citigroup
New York
$1K – – –
BRF
21
B. Riley Financial
California
– -$249K -764 Closed
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
– -$58K -179 Closed
VF
23
Virtu Financial
New York
– -$48K -149 Closed
Macquarie Group
24
Macquarie Group
Australia
– -$32K -99 Closed
ARTA
25
A.R.T. Advisors
New York
– -$27K -86 Closed
1
2

EVOK Hedge Fund Activity: Q1 2018 in Review

20 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2018, worth a combined $4.76M — down 26% from $6.45M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of EVOK and 0 opened new positions — a net loss of 7 holders — while 5 trimmed existing stakes and 3 added.

The largest buyer was PNC Financial Services Group, adding an estimated $34.2K. The largest seller was Sphera Funds Management, cutting an estimated $857K.

  • 20 institutional investors held Evoke Pharma (EVOK) as of Q1 2018, down from 27 in Q4 2017.
  • Funds reported $4.76M of Evoke Pharma stock for Q1 2018, down 26% quarter-over-quarter.
  • 0 funds opened new Evoke Pharma positions in Q1 2018 and 7 closed out, a net change of -7 holders.
  • The largest Evoke Pharma buyer in Q1 2018 was PNC Financial Services Group, an estimated $34.2K added.
  • The largest Evoke Pharma seller in Q1 2018 was Sphera Funds Management, an estimated $857K sold.

Based on aggregated 13F filings for Q1 2018.